Skip to content

Released May 5, 2022, after the close

10-Q filed May 9, 2022, 39 days after period end · 0001162194-22-000055

Q1 2022 · 10-Q
Revenue$26.50M−19.2% vs Q1 2021−30.7% vs Q4 2021
Net Income-$76.29MN/M vs Q1 2021N/M vs Q4 2021
EPS Diluted-$0.99N/M vs Q1 2021no prior Q4 2021 on file
Operating Income-$27,503,000N/M
Operating Cash Flow-$15,590,000N/M
Free Cash Flowderived-$16,458,000N/M
Margins · derived
Operating margin-103.8%−44.9 pt vs Q1 2021
Net margin-287.8%−230.4 pt vs Q1 2021

What the release said

The release

Same quarter

MetricQ1 2022Q1 2021Q1 2020Q1 2019
Revenue$26.50M$32.79M$27.62M$30.11M
Net Income-$76.29M-$18.82M-$15.98M-$25.47M
EPS Diluted-$0.99-$0.25-$0.23-$0.44

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR